Fuller H B Co (FUL) Q3 2026 Earnings Call Transcript

Hello, everyone. Thank you for joining us and welcome to the H.B. Fuller Q3 2026 Earnings Conference Call. After today's prepared remarks, we will host a question and answer session. If you would like to ask a question, please press star one to raise your hand. To withdraw your question, press star one again. I will now hand the conference over to Scott Jensen, Investor Relations. Scott, please go ahead.

Thank you, Operator. Welcome to H.B. Fuller's Third Quarter 2026 Investor Conference Call. Presenting today are Celeste Mastin, President and Chief Executive Officer, and John Corcoran, Executive Vice President and Chief Financial Officer. After our prepared remarks, we will have a question and answer session. Before we begin, let me remind everyone that our comments today will include references to certain non-GAAP financial measures. These measures are supplemental to the results determined in accordance with GAAP. We believe that these measures are useful to investors in understanding our operating performance and to compare our performance with other companies. Reconciliation of non-GAAP measures to the nearest GAAP measure are included in our earnings release. Unless otherwise noted, comments about revenue refer to organic revenue, and comments about EPS, EBITDA, and profit margins refer to adjusted non-GAAP measures. We will also be making forward-looking statements during this call. call. These statements are based on current expectations and assumptions that are subject to risks and uncertainties. Actual results could differ materially from these expectations due to factors covered in our earnings release, comments made during this call, and the risk factors detailed in our filings with the SEC, all of which are available on our website at investors.hbfuller.com. I will now turn the call over to Celeste Mastin. Celeste?

Thank you Scott and welcome to today's call. Through disciplined execution, we delivered strong revenue, EBITDA and EPS growth in the quarter and continued to improve profitability and advance toward our EBITDA margin target of greater than 20%. Pricing actions are offsetting higher raw material costs and our restructuring efforts continue to enhance operating leverage. With the anticipated closing of the AMS acquisition before year-end, we remain focused on strengthening our portfolio, executing our Quantum Leap program, and creating long-term value for shareholders. Turning to our consolidated results in the third quarter, revenue was up 5.2 percent year-on-year. Adjusting for foreign exchange and acquisitions, organic growth was 4.4 percent, driven by pricing of 7.4%, partially offset by lower volume year-on-year. From a profitability perspective, EBITDA of $187 million increased 9% year-on-year, and EBITDA margin expanded 80 basis points to 19.9%, with EPS up 21% versus the same period last year. The continued execution of our pricing actions drove EBITDA growth and margin expansion across all three GBUs, enabling us to successfully offset elevated raw material inflation. Now let me move on to review the performance in each of our segments in the third quarter. HHC delivered 6% organic revenue growth year over year in the quarter, with strength in hygiene, beverage labeling, and tape and label more than offsetting softness in packaging. EBITDA margins were 17.6%, up 70 basis points versus last year, reflecting double-digit pricing performance. EA delivered organic revenue growth of approximately 5% year-over-year, excluding solar, with continued strength in aerospace and general industries. Electronics softened in the quarter as chip shortages weighed on mobile phone production in Asia Pacific, a reversal from the strong growth we saw in the first half of the year. Including solar, organic revenue increased 1% in the quarter. We have now fully lapped the solar exit and do not anticipate a meaningful impact on EA or consolidated HB Fuller organic growth going forward. EA EBITDA margin was 23.8%, up 50 basis points versus last year, driven by favorable pricing and restructuring savings. BAS delivered another strong quarter, with organic revenue up 5% year-over-year. Growth was driven by strength in roofing and insulating glass, partially offset by softness in wood. Despite a muted construction environment, BAS delivered another quarter of consistent growth and solid execution, demonstrating the importance of the innovation the group has brought to market. EBITDA for BAS increased 8%, and EBITDA margins expanded 50 basis points year-on-year, driven primarily by the impact of positive price. Geographically, America's organic revenue was up 4% year-on-year, with positive organic growth in all three GBUs led by BAS up 9%. Positive organic growth was driven by strong performance in roofing, insulating glass, and aerospace market segments. In EIMEA, organic revenue increased 9% year-on-year, with positive price in all three GBUs and and strong volume growth in EA markets, including automotive and aerospace. Asia-Pacific organic revenue was up 4% year-on-year, excluding solar, driven by strength in HHC, particularly in packaging. Total organic revenue was approximately flat year-on-year, including solar. Now let me provide an update on the petrochemical supply chain disruption and what we're seeing as we enter the fourth quarter and look toward 2027 the dislocation continues to be a defining feature of our operating environment supply chains remain disjointed and we do not expect a normalization until well after the conflict subsides we acted quickly and decisively in response to this situation and have been successful in maintaining supply continuity for our customers and will continue to do so. On raw materials, prices have stabilized at elevated levels and we expect them to remain at or near current levels for at least the remainder of the year. As conditions warrant, we will judiciously raise price to offset raw material costs and protect our margins. We remain confident in our ability to continue mitigating inflationary pressure. Now let me take a moment to provide an update on Project Quantum Leap, our multi-year initiative to optimize our manufacturing and distribution network, improve factory utilization and service levels and increase the efficiency of our global supply chain. We continue to make good progress and implementation is tracking as expected. The team remains focused on disciplined execution and delivering the long-term benefits we've outlined. As a reminder, we began this project with 82 manufacturing facilities at the end of 2024. We expect to exit 2026 with approximately 62 facilities and, excluding AMS, further reduce the footprint to below 60 by the end of 2027 27 while progressing to our goal of 55 these actions are improving network efficiency while positioning us to better serve our customers with a more streamlined operating model from a financial perspective quantum leap remains a significant value creation opportunity we continue to target approximately 75 million dollars of annualized conversion cost savings by the end of 2030 through the end of 2026 we expect to have realized approximately 25 million of those benefits looking ahead we expect the program to deliver an additional 20 to 25 million of incremental savings in 2027 in support of this initiative we expect to invest 150 million of capital over the life of the program we plan to invest roughly 50 million of capital in 2026 and anticipate capital spending of less than 25 million in 2027 as key projects are completed with a further reduction in spending expected after 2027 we anticipate approximately 50 million of total one-time cash costs associated with the program with about a third of those already realized. Importantly, total one-time costs are projected to be more than offset by proceeds from real estate sales. Beyond direct cost savings, Quantum Leap is expected to generate substantial cash flow benefits through improved working capital efficiency, inventory reduction, and lower maintenance capital requirements. Overall, we remain on track and are even more confident today in quantum leap's ability to help enable meaningful earnings growth cash flow improvement and progress toward our long-term margin objectives now let me turn the call over to john corcoran to review our third quarter results in more detail and our updated outlook for the remainder of 2026. thank you celeste i'll begin with some additional financial details on the third quarter.

For the quarter, revenue was up 5.2% year-on-year. Currency and acquisitions contributed a positive 0.8%. Adjusting for those items, organic revenue was up 4.4% with pricing of 7.4% offset by lower volume. Adjusted gross profit margin was 33.5%, up 120 basis points versus last year, driven by pricing execution and restructuring savings. Adjusted selling, general, and administrative expense was up 8% year-over-year and down 7% sequentially from the second quarter of 2026, reflecting the timing of certain expenses. Adjusted EBITDA for the quarter of $187 million was up 9% versus last year as pricing execution and restructuring savings more than offset lower volume. Adjusted earnings per share of $1.52 was up 21% versus the same quarter in 2025, driven by higher operating income. Networking capital in the third quarter of fiscal 2026 was 18.5% of annualized net revenue, up 150 basis points year over year. The increase was primarily driven by actions taken to support Quantum Leap, as well as strategic inventory investments made to secure raw materials and ensure supply continuity for customers. Year-to-date cash flow from operations was $183 million, up 17% year-over-year, driven by higher income. At the end of the third quarter, net debt to adjusted EBITDA was slightly less than three times, down from 3.3 times at the end of the third quarter of last year. With that, let me now turn to our guidance for the 2026 fiscal year. Please note this outlook does not reflect the impact of our proposed acquisition of advanced medical solutions. Net revenue is still expected to be up mid-single digits, and organic revenue is still expected to be up low single digits versus fiscal 2025, with pricing up mid-single digits and volume down low single digits. Adjusted EBITDA for fiscal 2026 is now expected to be in the range of $655 million to $670 million, and adjusted EPS is now expected to be in the range of $4.70 to $4.85. Cash flow from operations, excluding AMS-related items, is still expected to be in the range of $300 to $325 million. Now let me turn the call back over to Celeste to wrap us up.

Thank you, John. The financial performance John outlined reflects the strength of our strategy and execution. A key contributor to that success is the way we partner with our customers to develop innovative solutions that improve performance, address complex challenges, and advance sustainability across the industries we serve. Last week, we announced the winners of our 2026 H.B. Fuller Customer Innovation Awards. These awards recognize customers who have developed solutions delivering measurable advances in sustainability, safety, and performance. Winners are selected based on innovation, market impact, technical achievement, and successful collaboration with H.B. Fuller teams. This year, we honored Ben Dasmal General Trading Company and Huda Maki for innovations that demonstrate the power of collaboration and technical expertise. Ben Dasmal was recognized for developing an innovative, prefabricated HVAC insulation system that improves protection against condensation and corrosion in hot, humid environments. Working together with H.B. Fuller, the company incorporated our foster neoclad protective vapor barrier technology into an off-site pre-fabrication process that reduces installation time, enhances long-term system reliability, and helps extend service life in demanding climate conditions. Huramaki was recognized for ProDairy, a recyclable paper-based dairy cup designed to reduce plastic use while maintaining the performance required for chilled food applications. Leveraging HB Fuller's adhesive and coating expertise, the solution significantly reduces polyethylene content, improves recyclability, and supports our customers' circular packaging managing goals without compromising product performance. The innovations recognized this year span diverse industries, but share a common objective, applying science, engineering, and collaboration to solve real-world challenges and make products and systems more sustainable, efficient, and reliable. We congratulate both award winners and thank all of our customers who continue to work alongside us to bring innovative solutions to market. Their success reinforces our confidence in the long-term growth opportunities created by our technical leadership, customer intimacy, and commitment to innovation. We look forward to celebrating both award winners here in St. Paul, Minnesota on Adhesive and Sealance Day on September 29th. Now let me provide a brief update on our proposed acquisition of advanced medical solutions. We continue to make strong progress through the required regulatory approval process and remain on track to close the transaction by year end. From a financial standpoint, we are committed to our deleveraging plan and expect leverage to return to our targeted range of two-and-a-half to three times within two years of closing, supported by the strong cash generation profile of the combined company, augmented by Quantum Leap. We remain confident in the strategic and financial merits of acquiring AMS. The transaction will enhance our portfolio, strengthen our position in attractive health care markets, and further support our long-term growth objectives. We look forward to welcoming the AMS team and sharing additional updates on our next call. In closing, our third quarter results demonstrate the steady progress we are making across the business. We are expanding margins, advancing our operating efficiency initiatives, and maintaining a disciplined approach to execution while also positioning the company for its next phase of growth. Taken together, these actions strengthen H.B. Fuller's foundation for long-term value creation. That concludes our prepared remarks for today. Operator, please open the line for questions.

We will now begin the question and answer session. If you would like to ask a question, please press star 1 to raise your hand. To withdraw your question, press star 1 again. We ask that you pick up your handset when asking a question to allow for optimum sound quality. If you are muted locally, please remember to unmute your device. Please stand by while we compile the Q&A roster. Your first question comes from the line of Mike Harrison with Seaport Research Partners. Mike, your line is now open.

Hi, good morning. Good morning, Mike. Mike? So you guys came in just above the midpoint of your guidance range for Q3, and it looks like volumes were not down as much as you had expected. I think you had guided to a down mid-single digit, and you were down three. Can you just kind of walk us through what came in different than you expected when you provided guidance, I guess, from both a volume perspective and maybe contributed to some of the margin strength that you were seeing?

Sure. Yeah, so as we looked at the second half, Mike, we had anticipated that we would see more customer constraints on materials outside of adhesives. We knew we could supply, but we were concerned that they would be able to get all of the materials they needed to produce their products. And while the market has been tight on a lot of materials, it hasn't been so much short. So that resulted in a little better volume performance than we anticipated. I would also add that the demand markets are fluctuating a lot more than they usually do. Our order patterns are fluctuating more than they usually do. You know, we're seeing instances where customers, you know, are especially mid and small size customers are in mass doubling the amount of time or the interval between their orders. And then sometimes they shrink rapidly, particularly when the headlines are out that the price of oil has dramatically increased. So it does make volume a little more difficult to predict in this environment. In this particular quarter, you know, we saw volumes much stronger at the end of the quarter than at the beginning of the quarter for the first couple of months, in fact. And that strength has continued into P10.

All right. And then I was hoping that you could talk a little bit about how we should think about volume trends as we're starting to turn our attention to fiscal 27. So last year, volumes were down a little bit. This year, you're probably tracking toward a down 3-ish percent number. Understanding some of that has been the solar business, and you said we're lapping that. But just curious, what's your confidence level that we can see volumes turn positive in fiscal 27? And I guess what end markets do you see the most risk around volumes over the next few quarters?

Okay, Mike, maybe I'll try to take this one and then Celeste can add commentary. So looking ahead to 2027, you know, focusing on things that are, let's say, specific to H.P. Fuller will have fully lapped, you know, the impact of our exit of solar. So that was sort of an overhang for three quarters this year. we're now beyond that it will be um you know it won't be an overhang next year um obviously closing of ams we're adding you know a higher growth um business i'd say there's a few markets in ea that that were challenged um and these are more external issues maybe i'll pivot to sort of external impacts um you certainly electronics has been challenged with chip shortages um you know We're hopeful that that is not an issue next year that's impacting both electronics and auto. And the construction markets have been very sluggish with high interest rates and the impact that's having on residential. Again, don't know whether that will be resolved next year or not, but if we were to see some movement there, that would be positive. And then in HAC, as you know, it's largely driven by large CPG customers, which have struggled. So it's probably more dependent on external forces and some of those I've named. But we have a couple of things as it relates to the portfolio improvements that we've made that should support better growth going forward.

Yeah, I would supplement that, Mike, by saying I think China is the region to watch for 2027. I was really pleased with our performance in Asia this quarter because despite the fact that there was the consumer environment in China's weak and that electronics, some of their export markets were off, we still performed very well in Asia thanks to HHC's ability to grow their business there and share in the packaging markets in particular. You know, Europe's looking up, and that's exciting. So I think it's less of a risk for us for 2027, more because we are gaining share in that region. Being a reliable supplier matters more there, and the ability to bring innovation to market matters. And then I would say that, yes, to John's point, while construction remains weak and is definitely something to watch, I feel strongly that our BAS business has brought innovation to market that has allowed them to continue to grow in a declining market. So, you know, I think watching construction, watching China are the key areas of risk for 27.

All right. Very helpful. Thanks very much.

Thanks, Mike. Your next question comes from the line of David Begleiter with Deutsche Bank. David, your line is now open.

Thank you. Good morning. Morning, David. Good morning. Looking just at HH and C the last two years, I show volumes down roughly 9%, maybe I'm a bit off, but I think in that range. Why is that? this is all just over the Q3 period last couple years.

Over the last two years. Yeah. So, I mean, if you think about HHC, I think one of the biggest challenges that HHC faces is a couple of market-wide changes. So, you know, one is certainly the introduction of the GLPs. A lot of our materials in HHC go into the packaging end markets, a lot less packaged food now being consumed. And you can see that in a number of the CPG food companies' results. And the second thing I would say is that's a business that I think sometimes we overlook is really very heavily influenced by household formation. And, you know, we aren't seeing residential home building happen. People are not moving as much for jobs. There's a lot less mobility. And so, you know, that weighs on, people aren't filling new cupboards. People aren't changing out materials in their homes. And so that also, I believe, has weighed on the HHC business in the last couple of years.

Understood. And just on AMS, how has the business been performed in the last two or three months? So I'm still on track with the projections you gave us back in late June.

Well, I can't comment on their performance in the last two or three months. What I would say is they did just announce their first half performance. I would refer you there. They They showed adjusted EBITDA improving by 8%, first half of 26 versus first half of 25, which is how they report. And they reported a 4% revenue increase over that same period of time. So, you know, we're really excited, David. You know, that's a business that we're looking forward to having in our portfolio. And as we look at that business and have made our own projections, you know, we think that's a business that will be growing about 8% a year on average. So good organic growth prospects there.

Thank you.

Your next question comes from a line of Gamshim Punjabi with Baird. Gamshim, your line is now open.

Thank you, Appir. Good morning, everybody. You know, Celeste, just following up on the last couple of questions, you know, specific to EA, do you sense any sort of change in the demand trend line in that segment? You know, I know solar has come through at this point. I think you mentioned electronics weakening due to chip shortages, and, you know, it looks like auto has started to weaken a little bit as well. So just curious as to the demand trend line there versus the rest of the portfolio.

Yeah, the EA business performed incredibly well in Europe in this last quarter and strong in the U.S. So overall, I don't see the segments compromised. In fact, automotive has bounced back in Q3 versus where it was in Q2. The real challenge in the EA business in Q3 was in Asia. particularly in China. Saw a slowdown in electronics, fewer shipments, VVs. And so that weighed on the business in the quarter. But the good news is now we are wrapping around that solar impact. So we'll be clear of that come Q4.

Yeah, and I can add just a little more detail on the trends because Celeste is right. If you adjust for solar, the business has been growing mid-single digits from a volume standpoint, low to mid-sickle digits, and it's very consistent. I think the only change from Q2 to Q3 in volume was largely driven by electronics, as Celeste mentioned.

Okay, that's helpful. And then in terms of the, you know, variances for fiscal year 27, you sort of gave some high-level view on volumes, at least as it relates to what to watch out for. You know, can you give us a bit more in terms of some of the variances at this point? I think you mentioned $25 million on EBITDA and incremental cost savings. You know, what about pricing flow through? And then on pricing, are you still implementing additional increases? I think you mentioned sort of a flattening of the raw material cost curve. But, you know, logistical costs and so on and so forth have gone up significantly over the last few months as well. So just curious as to the pricing contribution, the way you see it at this point for next year.

Yes. If you look at just overall next year, I would say high level. The way that the year will play out is you'll see some carryover of pricing and raw materials happen in that first half. That'll transition more to the benefits from quantum leap starting to flow through in the second half that we mentioned. As far as pricing, yes, the teams, as you know, got out early on price and started raising price in Q2. You know, our job isn't done. We continue to raise price judiciously where it's warranted. And I say that based on region and market segment and technology-based. So, yes, we are still implementing price increases, and we're anticipating that'll flow into the first half of next year.

Yeah, and I think, Gansom, just, you know, for purposes of kind of thinking about what the next year would look like, you know, at a high level from a P&L standpoint, and these comments exclude any impact of AMS. As Celeste mentioned, you know, we will have carryover pricing, but we'll have carryover raw material impact as well. And, you know, we got out quickly on pricing. Raw materials tend to lag. So, you know, as you look at this year, you know, we've got a positive spread between pricing and raws. We would expect that we would have, you know, a positive gap between pricing and raws next year, but not as significant as this year because we still have raws that we'll be rolling through. That'll primarily be a first half of the year phenomenon, as Celeste mentioned. We'll sort of have annualized against that, and probably there'll be very little difference between pricing and Roth, assuming markets don't move significantly, in the second half of the year. Quantum leap, as we said in our remarks, should contribute about $20 million to $25 million of incremental savings next year. That'll be more weighted to the back half of the year. And then we'll have the normal kind of inflation, merit increases, which have been in that $25 million range. So, you know, we see, you know, a view on 2027 that will grow, top line and bottom line. Obviously, carryover pricing will help that from both the top line and bottom line standpoint, as will Quantum Leap. And we'll provide, obviously, a lot more detail in our January call.

Okay. Very good. Thank you.

Thanks, Gontro.

Your next question comes from the line of Jeff Zekakis with J.P. Morgan. Jeff, your line is now open.

Thanks very much. I think in your prepared remarks, you talked about land sales that may be something like $33 million over the next year or so. Are these sale and leaseback structures, or is this pure sale of land? And is that the right amount of cash flow that may come to you?

So those are sales of manufacturing facilities and the land associated with those, Jeff. We're not going to lease those back. We're going to sell those facilities and we will use those proceeds to pay down the one-time costs that we'll experience with severance and other closure costs.

Thank you for that. And in terms of your prices, your prices for the quarter were up 7.4%, but that's the average number for the quarter. Where are they now? Are they higher than 7.4?

Yeah, we exited the quarter at 7.6%, Jeff, so we got a lot of that price early that's been working its way through, and that'll continue to tick up as we continue to adjust our pricing for any raw material changes that occur. You know, we talked about pricing on average, but, you know, It's true. Pricing changes happen differently in different regions or based on different technologies. So we've been very judicious and I would say responsible in our pricing. Our objective is to cover raw material cost increases and maintain our margin.

And that's what our plans continue to be for the upcoming year. um since since you reported your previous quarter there's been a fair amount of clamoring by your shareholder base wanting you to do this or or that um in the light of what your shareholders have said to you in any way have you changed the way you look um changed the way you plan to operate H.P. Fuller over the next year or two?

Yeah, so deleveraging will be a very, very high priority for us, as you can imagine, as soon as we close the AMS transaction, Jeff. In fact, we're already working hard on trying to bring our debt level down. And I would say there's going to be changes in a number of areas you know one of those is as i've said before every august our global market segment leaders come in they present their three-year strategy for the business you know we we do a rigorous portfolio review after that in fact you know it was um That's what prompted the sale of our flooring business in 2025, for example, and I'd say we've just been through that exercise here again in August, and coming out of that exercise, I'd say we're putting even more scrutiny and a much more critical lens on those business plans and really challenging ourselves to determine if we are in fact the best owner for every one of those market segments. So, you know, the possibility that we will divest something is something, you know, we're taking very seriously because we know it would accelerate reducing our leverage. You know, the other thing is we're at a nice point in Quantum Leap where we're going to be able to really generate more cash flow as a consequence of that. Maybe, John, if you want to walk through the improvements to cash flow that we're going to see because of Quantum Leap and because we're going to be able to operate differently because of the changes we're making through Quantum Leap.

Sure. And yeah, that is one of the reasons we feel good about our deleveraging plan is the cash flow benefits that Quantum Leap brings. Obviously, we've talked about the $75 million of reduced conversion costs, you know, with about $50 million to come. That's obviously an operating cash flow impact. But one of the key elements is with the changes we're making in our warehouse structure, we think we've got an opportunity to reduce working capital inventory specifically, substantially, at least five days, which would be $35 million of benefit in operating cash flow. And then in CapEx, you know, we'll see that come down. We've probably spent about $50 million related to enabling Quantum Leap this year in CapEx. As we said in our remarks, that'll be less than $25 million next year and eventually go to zero. And the fact that we're, you know, we're getting out of effectively a third of our plants, we would expect maintenance capital to come down, you know, by, you know, roughly a third, which would be $15 million dollars and then um project one is kind of our sap deployment what we call project one is coming to effectively an end in terms of implementation we have 97 of our revenue on on one instance of sap and we probably spend about 25 million dollars a year in capex on that um and that will will will be substantially less so so all of those things will be positive as it relates to our cash flow and our deleveraging plan. As Celeste said, if there was an opportunity to potentially divest something that could further accelerate that, we'd definitely look at it.

And then lastly, John, I think maybe your CapEx from AMS would go up $20 million or so. So, like, in a range of capital expenditures versus 2026, should your CapEx next year inclusive of the acquisition be up or down?

It should be down. And I think I think AMS will be a little less than the 20 million you quoted, but it'll be in the teens. But, yeah, we would say, you know, just related to certainly the fact we're getting through the heavier spend-related quantum leap and the working capital opportunity we see, or I'm sorry, on CapEx of the SAP project coming to an end, both of those things should result in a reduction in CapEx even with some additional capital from AMS.

Great. Thank you so much. Thanks, Jeff.

Your next question comes from the line of Patrick Cunningham with Citi. Patrick, your line is now open.

Hi, good morning. This is Alex on for Patrick. Good morning. My question was, good morning. So, you know, your modular expansion was quite striking in 3Q, despite the lower volume environment. Maybe can you help us with the cuts and takes on the price-cost expansion and maybe just your confidence on expanding margins into 27?

Sure.

Yeah, I can give a little bit of color on that. So the impact we're seeing is largely different by pricing execution relative to raw materials flowing through. As we discussed, we got out fast on pricing. A lot of that took place in the second quarter. We did take some additional actions. So in the third quarter, we get the benefit of actions that we're taking during the second quarter, flowing through to the third quarter. We had some new pricing actions. And raw materials are a bigger headwind this quarter than they were last quarter, but we had more pricing to offset that. So we sort of talked about this third quarter being sort of the period when we'll see that biggest gap between pricing and raws, and we would expect that to narrow a little bit next quarter simply because we'll see more raw material costs finally rolling through the P&L. But we're also getting savings related to Quantum Leap. By the end of this year, we'll have $25 million of savings that we've been able to achieve on a run rate basis, about $15 million this year, and that's kind of ramped up through the year. So those are really the two things that driven the margin expansion and yeah we think we will have margin expansion next year um for some of the same reasons as i said earlier you know pricing in raws should be positive you know less than this year but still positive and then quantum leap will have a bigger positive impact next year great um and as follow-up um just curious how should we think about like the stability of the growth uh for medical and market you know assuming a higher for longer rate environment you know relative to what the procedures and the surgeries?

Yeah, the medical, actually the use of surgical bonding is not just stable, but of high growth medical end market. And there's a number of reasons for that. I mean, certainly the number of procedures continues to increase even in a longer rate environment. We'll still see more procedures, and there's a growing number of smaller procedures, procedures where the use of adhesive is even more likely and accepted. And so we expect this medical end market to continue to grow quickly. In fact, that was one of the things we really liked about having it in our portfolio. It delivers strong organic growth at a high margin rate, and it allows us to balance out some of the cyclicality that we have in the industrial end markets as well as in the construction market. So we think it makes for a really nice, balanced portfolio, and it'll be that growth spark that endures even when the market is challenging.

Great. Thank you very much.

Thank you.

Your next question comes from the line of Kevin McCarthy with Vertical Research Partners. Kevin, your line is now open.

Yes, thank you very much, and good morning. John, can you elaborate on the financing for the AMS deal? I think you have fully committed financing in place, but maybe you can elaborate on, you know, what the medium-term plans are with regard to term structure and, you know, what does that cost of debt look like given the volatility in the bond market these days?

Sure. I'm happy to, Kevin. So, yeah, as you mentioned, we do have bridge financing in place, so we are, you know, we are assured to have financing. To close the transaction, You know, our plan would be to execute the takeout financing prior to close, having it contingent on the close. And we're quite far along, I would say, in planning for that. Expect to see strong interest and, you know, feel highly confident that we'll be successful. If you kind of look at, you know, the structure, that's still being discussed, but it'll probably be some combination of, you know, short-term, term loan B type loans and probably unsecured type bonds. We obviously want to make sure that we have ample amounts of debt that we can repay quickly because we plan to deliver quickly, so that'll be reflected in the structure. Financing rates, I would say right now, you know, kind of, you know, sort of eight year fixed rates are probably in the six and a half to seven percent range, you know, shorter rates, term loan B, they've kind of been pretty consistently around 175 to 200 basis points over SOFR. So that is kind of what we're seeing right now. And as I said, we'll be moving to finalize the financing before the deal closes.

Very helpful. And then, Celeste, you know, there's a lot of discussion previously on the call regarding your volume of minus 3% for the quarter, including GLP-1s and chip shortages and other factors. You know, if I just kind of zoom out the lens and think about your demand function for adhesives relative to macrometrics? Do you have in your mind that it should reconverge with macrometrics over some period of time, whether that's six months or 18 months or some other period? How do you think about that future trajectory?

Yeah, it's so hard to index this business against a collection of macrometrics because we are in so many different end markets in so many different regions. And when you think about it, big picture, it's an $80 billion market and we're less than 5% market share. And so being able to dial in volumes in the adhesive space versus a macro collection of indices is really hard. You know, one of the things that we do in the adhesives industry is, you know, we bring to our customers high-mileage adhesives. What I mean by that is, you know, they'll start using an adhesive, and in order to further optimize production, a lot of times we'll work with them to bring them a higher value, and you see that in higher price. adhesive that they can use less of. And so that's a dynamic that's constantly occurring in this market. And so there's a component of that that you see that really disassociates it from the macro trends, particularly the fact that our share is so low. You'll see it in a lot of our spaces, You know, when construction or automotive are doing badly or when the number of, you know, mobile phone handsets is declining, we will still be growing our business in those spaces, largely because we're able to take share through technology and because we have a low share position.

I see. Very helpful. Thank you for the color.

Your next question comes from the line of Lucas Beaumont with UBS. Lucas, your line is now open.

Good morning. Good morning. Putting together all your comments kind of on the call today, just trying to sort of think about, like, the high-level considerations for the business as we go into next year. And so, I mean, based on your fourth quarter guide, I mean, it looks like you're going to be sort of exiting with high single-digit pricing, volumes are kind of down, on low single digits, continued kind of cost pressure to sort of come on the raw material side. Sounds like the volume outlook's kind of being choppy across sort of different end markets and that could remain under pressure as we sort of go into next year as well. I mean, you're going to have some benefits from easier comps, I guess, from solar and just the declines from this year. But I mean, overall, this seems like a setup that might point to more constrained growth into next year before the AMS acquisition. I mean, putting all of that together, it probably points to something more in the low to mid single digit kind of EBITDA growth range, more like what you had in 2024 and 2025 than the high single digits you're kind of tracking towards this year. So I guess just how would you sort of put all that together for us and any other considerations or upside factors that we should sort of work into our outlook there as well? Thanks.

So, Lucas, I'll add a little color, and you kind of recapped some of the key drivers of next year from a financial assumption standpoint. You know, and I would say, I don't know that I'd conclude, you know, low single-digit or even mid-single-digit EBITDA growth yet, I think, and we'll come forward with all of that in January. It obviously depends on the broader macro, and we'll probably have more of a view on that in three and a half, four months. But I think we still think there's a lot of benefit that is specific to the things that we're doing from an execution standpoint. As I mentioned, the pricing raw benefit will be positive next year, and we're ready to, as Celeste said, judicially take additional actions if we need to. And the quantum leap savings are meaningful. So we'll lay that all out. I think you've got the right key considerations and we'll provide a sort of picture as to where that gets us. But we'll grow, right? We'll grow, we grow, we'll grow next year. We grew this year, we grew last year. So we will grow.

Yeah. And I think, you know, you, the, I would also, I'm also positive about next year, particularly because when you look at our, again, our position in this industry, it's a $80 billion industry and our share is less than 5%. And we now have, you know, teams that are working hard, hitting on all cylinders to deliver great innovation to our customers. And it's making a difference. You know, just look at BAS. That's a very constrained market, particularly here in the U.S., yet that team has introduced new products that they have used to grow share. In fact, we put out a price increase on Monday where we announced the expansion of our 4SG cofinity product range with really some new products that have decidedly better benefits for our customers and building owners. And so, you know, that is the way that we are going to continue to drive improvement in EBITDA. It's not just, you know, pricing and the regular volume mix it's bringing innovation and it's also delivering on our quantum leap commitment which is on track as john indicated and will at its conclusion deliver 75 million dollars of run rate savings uh that will influence evita very favorably right thanks um and then i guess just just given kind of the macro environment sort of challenges currently um that are so choppy um i guess how do you how do you sort of see that impacting the outlook for uh the ams business i

mean just talk us through how defensive you sort of view their sales and earnings uh compared to like other parts of the portfolio i guess if uh 2027 ends up being a bit more challenged from a macro perspective i guess do you see that adding any risks on the uh synergy or sort of earnings target side and also just around your deleveraging considerations into it. Thanks.

No, in fact, the AMS team, you know, continues to make really good progress on their Peter's surgical synergies. So when we quoted our synergy target, recall that we were getting the benefit of synergies related to their closure of five facilities. And they are well on track and delivering on that commitment. So we end up stepping into the business when there's already synergies in flight, which is very helpful. Now, when you look at the market structure, It's a market, as I indicated before, that's growing rapidly. The use of tissue bonding in surgical procedures continues to grow. The combination of the two businesses makes us the second largest surgical tissue bonding company in the world. And that's a position where we anticipate not feeling the challenges of the macro environment, but more so being able to expand the business in that environment because it's less oriented to the fluctuations of the industrial or the construction spaces that we're in today.

Thanks very much.

Thanks, Lucas.

Our last question comes from the line of Mike Harrison with Seaport Research Partners. Mike, your line is now open.

One more for me. I appreciate you giving me the chance to ask this one. Just on the BAS offer, the unsolicited proposal that you guys received, the board rejected that proposal. And one of the reasons that was noted was some dis-synergies that would be associated with shared plants and maybe reduced scale and procurement impacts. Can you help us quantify those dis-synergies at all? And I guess I'm curious how you're thinking about it. Is there a price for BAS at which, you know, a divestiture could still make sense, even though there are maybe some heavy lifting that would be required in carving that out?

Yeah, so, you know, the board fairly considered the offer for BAS. And in any case, if we receive an offer for a component of the business or the business itself, the board's going to do its fiduciary duties and fully evaluate that. In the case of BAS, as we indicated, it's significantly integrated into the company as a whole. And that's not unusual. In fact, if you look at our business, you know, we have now 62 plants around the world that generally produce two or three different materials and produce them for, you know, 15 to 20 different market segments. So, you know, they are assigned to a GBU that's more for management purposes. They, in fact, are technology-based. And so we have a lot of businesses here that are really entwined like that, as you would expect, in our production and sourcing, raw material sourcing environment.

In this case, we think that we're the best owner of BAS. but we're always open-minded and willing to consider other alternatives that make sense yeah and i can comment a little bit on just you know the synergies that as opposed to quantifying them i'll kind of describe you know where they come from and then you know how we think about them in light of a potential divestiture you know there's obviously stranded costs that you're always going to have with a divestiture we did with flooring um flooring was a business that was relatively untangled with our other businesses. We had six dedicated manufacturing plants for flooring. The materials they bought were fairly unique to the flooring business. With BAS, you know, they probably manufacture in 25, 30 different manufacturing facilities, probably two-thirds of which they're sharing with the other businesses. So they don't have a lot of dedicated plants. So that creates some disenergies. On the sourcing side, EAS is roughly 20% of HP Fuller's revenue. They probably represent about 35 to 40% of the solvents we buy. So that would have a significant impact from our purchasing power as it relates to that material, which would impact other businesses. So those are the things we look at. And we can overcome all of those, right, depending on the potential valuation of a sale of an asset. But they're real considerations, and they were meaningful enough with BAS that we thought we should mention them.

All right. Thanks very much.

Thanks, Mike. We have reached the end of our Q&A session. I will now turn the call back to Celeste for closing remarks.

Thanks very much for joining us this quarter. We look forward to talking to you in January.

This concludes today's call. Thank you for attending. You may now disconnect.